ストックスクリーナーアプリを入手
3.51
0.57%
-0.02
プレマーケット:
3.37
-0.14
-3.99%
前日終値:
$3.53
開ける：
$3.51
24時間の取引高:
22,359
Relative Volume:
0.19
時価総額：
$8.68M
収益：
$960.60K
当期純損益:
$-7.01M
株価収益率:
-1.32
EPS:
-2.659
ネットキャッシュフロー:
$-7.78M
1週間 パフォーマンス:
-3.31%
1か月 パフォーマンス:
-9.18%
6か月 パフォーマンス:
-42.86%
1年 パフォーマンス:
-48.98%
1日の値動き範囲:
$3.41
$3.5299
1週間の範囲:
$3.41
$3.71
52週間の値動き範囲:
$1.8301
$32.00
Soligenix Inc Stock (SNGX) Company Profile
SNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| SNGX | 3.51 | 8.68M | 960.60K | -7.01M | -7.78M | -2.659 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
| 2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 繰り返されました | Maxim Group | Buy |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - Nasdaq
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels - AOL
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease - Marketscreener.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - Nasdaq
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024 - MSN
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) - Yahoo Finance
Soligenix Inc. (SNGX) Quarterly 10-Q Report - Quartz
SEC Form 424B3 filed by Soligenix Inc. - Quantisnow
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - citybiz
Soligenix Reports Q3 Loss, Advances Clinical Pipeline with $9.8M Cash Position | SNGX Stock News - StockTitan
Soligenix Granted FDA Orphan Drug Designation For SuVax Active Ingredient - Contract Pharma
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference - GlobeNewswire
Soligenix gains Hong Kong patent for synthetic hypericin - Investing.com India
Soligenix to Present at Upcoming Conferences - GuruFocus.com
Soligenix gains Hong Kong patent for synthetic hypericin By Investing.com - Investing.com Nigeria
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - Lelezard
Soligenix Invited to Present at Upcoming Investor Conferences - StockTitan
Soligenix secures amended loan terms with Pontifax Medison - Investing.com India
Soligenix secures amended loan terms with Pontifax Medison By Investing.com - Investing.com UK
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference - PR Newswire
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference - Marketscreener.com
A stock that deserves closer examination: Soligenix Inc (SNGX) - US Post News
Soligenix partners with Sterling to scale hypericin production By Investing.com - Investing.com Australia
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development - Research Tree
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… - Zacks Small Cap Research
Soligenix partners with Sterling to scale hypericin production - Investing.com India
Soligenix Announces Partnership with Sterling Pharma Solutions - Lelezard
Indo-Asian News Service-SOLIGENIX ANNOUNCES PARTNERSHIP WITH STERLING PHARMA SOLUTIONS - IANS India Pvt Ltd
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 - cnhinews.com
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Swvl expands Saudi Arabia presence with new contracts By Investing.com - Investing.com Canada
Southern (NYSE:SO) Lowered to “Neutral” at Mizuho - Defense World
Luna Aura introduces Sofia Andres as first celebrity endorser for Hope Glow Super Glutathione Capsules - LionhearTV
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
6.90%
大文字化:
|
ボリューム (24 時間):